Special Issue

Epigenetics and Cancer Immunotherapy

Message from the Guest Editor

Tumor escape from the immune system relies on a variety of mechanisms, often based on a profound reorganization of tumor cell's epigenome, alteration of the TME and tumor-driven rewiring of immune cells chromatin landscape. Immunotherapy has emerged as a therapeutic alternative to conventional drugs and has revolutionized cancer treatment, by boosting the patient ´s antitumor immune response to effectively destroy the malignant cells and prevent cancer progression and expansion. There is growing evidence that epigenetic regulation has a key role in the modulation of anti-tumor immune responses by reshaping the TME and contributing to control immune recognition and immunogenicity. Tumor driven immune suppression can be overcome with epigenetic based drugs that inhibit the activity of epigenetic modifiers such DNA methyltransferase and histone deacetylases, promoting the expression of tumor-associated antigens, immune checkpoint inhibitors, chemokines, and other immune-related genes. For that reason, the leverage of epigenetic changes controlling tumor-associated immune response to reinforce immunotherapy is a promising path of therapeutic intervention for cancer patients.

Guest Editor

Dr. Damiana Álvarez-Errico
Josep Carreras Leukaemia Research Institute (IJC), 08916 Badalona, Spain

Deadline for manuscript submissions

closed (30 January 2022)

Cancers

an Open Access Journal by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed

mdpi.com/si/67603

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

mdpi.com/journal/cancers

Cancers

an Open Access Journal by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed

mdpi.com/journal/cancers

MDPI

About the Journal

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok
Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)